FDA clears targeted cholangiocarcinoma therapy
-
By
-
Kathryn Wighton
-
September 24, 2026
-
2 min
By
Kathryn Wighton
September 24, 2026
Estimated genetic heritability was 11.8% using hearing thresholds versus 2.9% using diagnostic codes.
November 13, 2026
Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.
September 15, 2026
Optical analysis of resection-margin tissue identified tumor infiltration as the strongest contributor to predictions of where glioblastoma later recurred.
October 15, 2026